The GI tract is another huge target for pharmaceutical development and we have validated assays available in almost all regions including stomach and the small and large intestine and we are able to provide efficacy information on treatments designed to effect changes in motility, inflammation or drug absorption.
As with most other tissue types, tissue is available from both healthy and diseased individuals and tissue from patients suffering from inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are available.
Inflammation of the mucosa is a defining feature of many GI disorders, most notably Crohn’s disease and ulcerative colitis. Biopta can secure tissue from these patients and using our organoculture model we are able to examine production of cytokines or other endogenous mediators at baseline level and in response to your test compounds.
Prediction of gut permeability is also possible using human small intestinal tissue. Rather than use the Caco-2 cell line which can be inaccurate when used to predict the absorption of test compounds that are actively or poorly absorbed by the gut, Biopta use the small intestinal mucosa to determine permeability or bioavailability using the Ussing chamber.
Download GI Foresight PDF